Literature DB >> 15719270

Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome.

Piotr Rieske1, Magdalena Zakrzewska, Wojciech Biernat, Jacek Bartkowiak, Arthur Zimmermann, Paweł Piotr Liberski.   

Abstract

We observed three neoplasms with completely different histologies: malignant fibrous histiocytoma (MFH), atypical meningioma (AM), and glioblastoma (GB), developing in a patient with Li-Fraumeni syndrome. By using a combined molecular approach we performed molecular characterization of all three tumours. Data obtained showed an interesting molecular background of the AM and GB. AM showed TP53mutations and a 22q loss of heterozygosity (LOH). GB showed epidermal growth factor receptor (EGFR) amplification and TP53 mutations, whereas P16, PTEN, Rbwere intact in terms of LOH and/or multiplex PCR (polymerase chain reaction) analysis. Additionally, GB has a 1q LOH, which is an extremely rare alteration in glioblastomas. Identical 1q LOH was also observed in MFH.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15719270     DOI： 10.1007/s11060-004-9181-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  14 in total

1.  Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.

Authors:  P Rieske; J Bartkowiak; A Szadowska; M Debiec-Rychter
Journal:  Mol Pathol       Date:  1999-04

2.  Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.

Authors:  Eric C Burton; Kathleen R Lamborn; Peter Forsyth; James Scott; Jason O'Campo; Jane Uyehara-Lock; Michael Prados; Mitchel Berger; Sandra Passe; Joon Uhm; Brian P O'Neill; Robert B Jenkins; Ken D Aldape
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

Review 3.  Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization.

Authors:  T Nishizaki; S Ozaki; K Harada; H Ito; H Arai; T Beppu; K Sasaki
Journal:  Genes Chromosomes Cancer       Date:  1998-04       Impact factor: 5.006

4.  Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas.

Authors:  R M Bohle; S Brettreich; R Repp; A Borkhardt; H Kosmehl; H M Altmannsberger
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

5.  A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors.

Authors:  A Waha; B Rollbrocker; O D Wiestler; A von Deimling
Journal:  Diagn Mol Pathol       Date:  1996-06

6.  Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas.

Authors:  J Derré; R Lagacé; A Nicolas; A Mairal; F Chibon; J M Coindre; P Terrier; X Sastre; A Aurias
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

7.  TP53 mutations in human meningiomas.

Authors:  F M Verheijen; M Sprong; J M E Kloosterman; G Blaauw; J H H Thijssen; M A Blankenstein
Journal:  Int J Biol Markers       Date:  2002 Jan-Mar       Impact factor: 2.659

8.  The effect of tissue-specific growth patterns of target stem cells on the spectrum of tumours resulting from multistage tumorigenesis.

Authors:  J H Mao; K A Lindsay; R J Mairs; T E Wheldon
Journal:  J Theor Biol       Date:  2001-05-07       Impact factor: 2.691

9.  Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCP.

Authors:  Susan Erster; Neda Slade; Ute M Moll
Journal:  Methods Mol Biol       Date:  2003

10.  INI1 mutations in meningiomas at a potential hotspot in exon 9.

Authors:  U Schmitz; W Mueller; M Weber; N Sévenet; O Delattre; A von Deimling
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640
View more
  8 in total

1.  25-year-old woman with new-onset seizures.

Authors:  Peter L Konieczny; Ronald Reimer
Journal:  Mayo Clin Proc       Date:  2009-03       Impact factor: 7.616

2.  A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma.

Authors:  Yoyo Wing-Yiu Chu; Daniel Ka Leung Cheuk; Brian Hon Yin Chung; Naomi L Bowers; Shau-Yin Ha; Alan Kwok-Shing Chiang; Godfrey Chi-Fung Chan
Journal:  BMJ Case Rep       Date:  2014-11-18

3.  TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.

Authors:  Raissa Coelho Andrade; Anna Claudia Evangelista Dos Santos; Joaquim Caetano de Aguirre Neto; Julián Nevado; Pablo Lapunzina; Fernando Regla Vargas
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

4.  p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma.

Authors:  Lucja Fiszer-Maliszewska; Bernarda Kazanowska; Joanna Padzik
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

Review 5.  Glioblastoma simultaneously present with adjacent meningioma: case report and review of the literature.

Authors:  Kengo Suzuki; Hiroyuki Momota; Akiko Tonooka; Hiroko Noguchi; Kouhei Yamamoto; Masahiko Wanibuchi; Yoshihiro Minamida; Tadashi Hasegawa; Kiyohiro Houkin
Journal:  J Neurooncol       Date:  2010-01-10       Impact factor: 4.130

6.  Analysis of a synchronous gliosarcoma and meningioma with long survival: A case report and review of the literature.

Authors:  Paulo Linhares; Olga Martinho; Bruno Carvalho; Lígia Castro; José Manuel Lopes; Rui Vaz; Rui Manuel Reis
Journal:  Surg Neurol Int       Date:  2013-11-27

7.  cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.

Authors:  Malgorzata Szybka; Magdalena Zakrzewska; Piotr Rieske; Grazyna Pasz-Walczak; Dominika Kulczycka-Wojdala; Izabela Zawlik; Robert Stawski; Dorota Jesionek-Kupnicka; Pawel P Liberski; Radzislaw Kordek
Journal:  BMC Cancer       Date:  2009-08-11       Impact factor: 4.430

8.  Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility.

Authors:  Tuomo Mantere; Robert Winqvist; Saila Kauppila; Mervi Grip; Arja Jukkola-Vuorinen; Anna Tervasmäki; Katrin Rapakko; Katri Pylkäs
Journal:  PLoS Genet       Date:  2016-01-28       Impact factor: 5.917
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.